Sphingolipids mediate lipotoxicity in muscular dystrophies

References

[1] Datta N, Ghosh PS. Update on muscular dystrophies with focus on novel treatments and biomarkers. Curr Neurol Neurosci Rep 2020;20:14.

[2] Deconinck N, Dan B. Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007;36:1–7.

[3] Hannun YA, Obeid LM. Sphingolipids and their metabolism in physiology and disease. Nat Rev Mol Cell Biol 2018;19:175–91.

[4] Summers SA, Chaurasia B, Holland WL. Metabolic messengers: ceramides. Nat Metab 2019;1:1051–8.

[5] Laurila PP, Luan P, Wohlwend M, et al. Inhibition of sphingolipid de novo synthesis counteracts muscular dystrophy. Sci Adv 2022;8:eabh4423.

[6] Miyake Y, Kozutsumi Y, Nakamura S, et al. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995;211:396–403.

[7] Li CW, Yu K, Shyh-Chang N, et al. Pathogenesis of sarcopenia and the relationship with fat mass: descriptive review. J Cachexia Sarcopenia Muscle 2022;13:781–94.

[8] Chaurasia B, Summers SA. Ceramides in metabolism: key lipotoxic players. Annu Rev Physiol 2021;83:303–30.

[9] Rodríguez-Cruz M, Sanchez R, Escobar RE, et al. Evidence of insulin resistance and other metabolic alterations in boys with duchenne or becker muscular dystrophy. Int J Endocrinol 2015;2015:867273.

[10] Ma S, Shyh-Chang N. The metabaging cycle. Cell Prolif 2022;55:e13197.

RIGHTS & PERMISSIONS

The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.